Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Loco-regional management after neoadjuvant chemotherapy

BGICC 2023

19 - 20 Jan 2023

Published: 1 Feb 2023

Views: 21

Rating:

Save

Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA

Prof Terry Mamounas speaks to ecancer at BGICC 2023 about using genomic profiling for prediction of risk of loco-regional recurrence of tumours.

He explains the background of genomic classifiers.

Prof Mamounas also explores the potential future clinical implications of this area of study.

Related Videos

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti...

Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity ( Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy )

Metastatic bone disease: Importance of bone-targeted agents

Dr Alastair Greystoke - Newcastle University, Newcastle, UK and Prof Robert...

Metastatic bone disease: Importance of bone-targeted agents ( Dr Alastair Greystoke - Newcastle University, Newcastle, UK and Prof Robert Coleman - The University of Sheffield, Sheffield, UK )

Latest in PARP inhibitors and combination therapies for prostate cancer

Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni...

Latest in PARP inhibitors and combination therapies for prostate cancer ( Dr Dan George, Prof Noel Clarke, Dr Friederike Schlurmann and Prof Eleni Efstathiou )

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC...

Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San...

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )

Comment: LUMINA results show that women with low levels of the Ki67 biomarker...

Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )

Biomarker guidance allows patients 55 or older with low-grade luminal A-type...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis...

Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio...

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

More from ecancer